No Genetic Overlap between Circulating Iron Levels and Alzheimer's Disease by Lupton, Michelle K. et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.3233/JAD-170027
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Lupton, M. K., Benyamin, B., Proitsi, P., Nyholt, D. R., Ferreira, M. A., Montgomery, G. W., ... Whitfield, J. B.
(2017). No Genetic Overlap between Circulating Iron Levels and Alzheimer's Disease. JOURNAL OF
ALZHEIMERS DISEASE, 59(1), 85-99. DOI: 10.3233/JAD-170027
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 28. Feb. 2018
 
1 
 
No genetic overlap between circulating iron levels and Alzheimer’s disease 
Michelle K Luptona*, Beben Benyaminb, Petroula Proitsic, Dale R Nyholta,d, Manuel A 
Ferreiraa, Grant W Montgomerya, Andrew C Heathe, Pamela A Maddene, Sarah E Medlanda, 
Scott D Gordona, GERAD1 Consortium+, the Alzheimer’s Disease Neuroimaging Initiative++, 
Simon Lovestonef, Magda Tsolakig, Iwona Kloszewskah, Hilkka Soinineni, Patrizia Mecoccij; 
Bruno Velask, John F Powellc, Ashley I Bushl, Margaret J Wrighta,b,m, Nicholas G Martina, 
John B Whitfielda. 
a. QIMR Berghofer Medical Research Institute, Brisbane, Australia. 
b. Queensland Brain Institute, University of Queensland, Brisbane, Australia.  
c. Institute of Psychiatry Psychology and Neuroscience, Kings College London, UK 
d. Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, 
Australia. 
e. Washington University School of Medicine, St Louis, MO, USA. 
f. University of Oxford, Department of Psychiatry, Warneford Hospital, Oxford, United Kingdom. 
g. Memory and Dementia Centre, 3rd Department of Neurology, Aristotle University of Thessaloniki, 
Thessaloniki, Greece. 
h. Department of Old Age Psychiatry & Psychotic Disorders, Medical University of Lodz, Lodz, Poland. 
i. Department of Neurology, University of Eastern Finland and Kuopio University Hospital, Kuopio, 
Finland. 
j. Section of Gerontology and Geriatrics, Department of Medicine, University of Perugia, Perugia, Italy. 
k. Gerontopole, CHU, UMR INSERM 1027, University of Toulouse, France . 
l. Florey Institute of Neuroscience & Mental Health, University of Melbourne, Parkville, Australia. 
m. Centre for Advanced Imaging, University of Queensland, Brisbane, Australia. 
* Correspondence to Michelle K Lupton PhD. QIMR Berghofer Medical Research Institute. 300 Herston Road, 
Herston QLD 4030, Australia. Tel.: 61-7-3845-3947; Fax: 61-7-3362-0101.E-mail address: 
Michelle.Lupton@QIMRBerghofer.edu.au 
 
+Data used in the preparation of this article were obtained from the Genetic and Environmental Risk for 
Alzheimer’s disease (GERAD1) Consortium. As such, the investigators within the GERAD1 consortia 
contributed to the design and implementation of GERAD1 and/or provided data but did not participate in 
analysis or writing of this report (except those who are named authors). Membership of the GERAD1 
Consortium is provided in the Acknowledgments section. 
 
++Data used in preparing this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative 
(ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and 
implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. A 
complete listing of ADNI investigators may be found at: http://adni.loni.usc.edu/wp-
content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf 
 
Running title: Effect of circulating iron levels on AD risk 
  
 
2 
 
Abstract  
Iron deposition in the brain is a prominent feature of Alzheimer’s disease (AD). Recently, 
peripheral iron measures have also been shown to be associated with AD status. However, it 
is not known whether these associations are causal: do elevated or depleted iron levels 
throughout life have an effect on AD risk?  
We evaluate the  effects of peripheral iron on AD risk using a genetic profile score (GPS) 
approach by testing whether variants affecting iron, transferrin or ferritin levels selected from 
GWAS meta analysis of approximately 24,000 individuals are also associated with AD risk in 
an independent case-control cohort (n~10,000). Conversely, we test whether AD risk variants 
from a GWAS meta analysis of approximately 54,000 account for any variance in iron 
measures (n~9000).  
We do not identify a genetic relationship, suggesting that peripheral iron is not causal in the 
initiation of AD pathology.    
 
Keywords 
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Introduction 
Iron is the most abundant metal in the brain, where it is vital for neurotransmitter synthesis, 
myelination of neurons and energy generation by mitochondria [1]. However excess iron 
contributes to the generation of reactive oxygen species, and consequent tissue damage [2].  
Dysfunctional brain iron homeostasis is believed to play an important role in Alzheimer’s 
disease (AD) [3]. Iron accumulation is seen in the AD post-mortem brain [4] and iron content 
correlates with disease duration and mini-mental state examination (MMSE) score [5, 6].  
Individuals with mild cognitive impairment (MCI) with high risk of AD, showed higher 
cortical iron in vivo using MRI (measured using quantitative susceptibility mapping (QSM) 
techniques), which spatially co-localised with Aβ plaques and correlated with higher plaque 
load [7]. In addition, transferrin (an iron transport protein) and ferritin (an intracellular iron 
storage protein) are both elevated in AD brain tissue in neurodegenerative regions [8]. 
Ferritin levels in cerebrospinal fluid (CSF) negatively correlated with cognitive performance 
and predicted conversion from mild cognitive impairment (MCI) to AD [9]. Ferritin levels 
were also associated with CSF apolipoprotein E levels and were elevated by the Alzheimer’s 
risk allele, APOE-ε4, suggesting that ferritin may reflect the mechanism by which APOE-ε4 
is a risk factor for AD.  
Iron trafficking across the blood brain barrier is tightly regulated and early studies suggested 
that the brain is protected from systemic fluctuations in iron, with a lack of correlation 
between liver and brain iron concentrations post-mortem [10, 11]. Animal studies went on to 
challenge this view, showing that excess dietary iron increased brain iron levels in specific 
brain regions [12]. Quantitative MRI studies measuring the proton transverse relaxation rate 
(R2) now allow iron concentrations to be assessed in the brain in vivo. One such study in 
cognitively normal elderly men found that iron levels in basal ganglia structures were 
correlated with serum iron measures [13]. In an investigation in the large Australian Imaging 
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Biomarker and Lifestyle (AIBL) cohort of healthy controls, MCI and AD patients had 
disturbed brain iron metabolism reflected in the periphery by a decrease in plasma iron and 
haemoglobin [14], which was due to a deficiency of  iron-loading onto Transferrin [15]. 
Several mechanisms have been suggested to cause dysregulation of iron transport across the 
blood brain barrier in AD including the involvement of amyloid precursor protein (APP) 
fragments and chronic inflammation [11]. A deficit in brain iron trafficking, which is 
essential for heme formation, neurotransmitter synthesis, and myelination of axons, could 
contribute to the pathophysiology of AD. But results are inconsistent, with two meta analyses 
having differing conclusions on whether differences in circulating iron levels can be detected 
between AD cases and controls, and reporting heterogeneity between studies [16, 17].    
 
It is clear that iron dysregulation has a role in AD, and that to a limited extent plasma iron 
might reflect changes in brain iron levels, but there has been little investigation of whether 
peripheral iron levels over the long term affect risk of AD. Apart from the lack of suitable 
and adequately powered prospective studies, a limitation of observational studies is the 
inability to distinguish between causal associations and those due to confounding and reverse 
causation. A systematic review found that, in a limited number of trials, testing whether 
depletion or supplementation of iron changed a person’s risk of AD provided no conclusive 
evidence, and that additional studies are necessary [18].  
 
Drug development and randomised clinical trials are expensive and take many years to reach 
fruition, especially for a slowly progressive disease where treatment needs to start early in the 
disease course. An alternative approach, which overcomes the problem of reverse causation, 
is Mendelian Randomization (MR). Here the genetic variants affecting the putative causal 
variable are used as instrumental variables to test for an effect on disease risk. A 
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demonstration that genetic polymorphisms known to modify the phenotype level also modify 
disease risk provides indirect evidence of a causal association between phenotype and 
disease. MR analysis has the following assumptions: firstly the genetic variant used is only 
associated with the risk factor of interest; secondly it is independent of all confounding 
variables; and finally there is no causal pathway leading from the genetic variant to the 
disease except through the risk factor of interest.  For highly polygenic traits a large number 
of genetic polymorphisms can be combined to explain a larger proportion of the variance of 
the trait. The large numbers of variants included means that some are likely to violate the 
assumptions for a MR analysis. But a lack of association between appropriate SNPs and the 
outcome, given a dataset large enough to give reasonable power suggests that there is no 
causal relationship. A shared genetic basis indicates either, pleiotropy where a variant affects 
multiple traits independently, or a causal relationship between the two correlated traits; with 
the requirement that any potential confounders must be taken into account. If a shared genetic 
basis is found then a quantitative MR approach would then be required to compare direct and 
mediated paths between variants affecting the postulated causal variables and the outcome. 
This method has been widely used, both confirming and refuting suggested causal 
relationships based on epidemiological findings [19]. For example, this approach has had 
significant success in clarifying relationships between lipid levels and ischemic heart disease 
[20]. In addition a recent study compared 42 traits or diseases with available large GWAS 
where among other findings the authors found evidence that increased BMI causally 
increases triglyceride levels [21].  
 
MR was recently used to test for an effect of serum iron on Parkinson’s Disease (PD) risk, 
using three genetic variants influencing iron levels (HFE rs1800562, HFE rs1799945, and 
TMPRSS6 rs855791)[22]. The combined MR estimate showed a statistically significant 
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protective effect of increased serum iron in PD, suggesting that over the course of a life time 
alteration in tissue iron homeostasis reflected by a decrease in serum iron levels is on the 
causal pathway in the pathogenesis of PD. Twelve iron associated SNPs identified though 
GWAS were also used to investigate the role of iron in atherosclerosis, and identified a 
potential causal role in women [23].  
 
Single genetic variants that influence serum iron levels have not been shown to have a large 
effect on AD risk. The transferrin genetic variant C2 has been investigated and shown to have 
a small but significant association (OR=1.11, 95% CI 1.05 to 1.17, in a meta analysis of 19 
studies [24]). Several studies previously reported an increased frequency of the HFE H63D 
(rs1799945) mutation in AD patients [25], but these findings have not been replicated in the 
largest AD GWAS meta analysis [26]. There is evidence of interaction effects, which would 
not be apparent in GWAS meta analyses, involving H63D and APOE ε4 alleles where the 
combination appears to affect age of onset and, to a lesser extent, risk [27-29].  
 
Since several genes are well characterized for their impact on peripheral iron variation, we 
sought to determine their combined causal effect on AD risk. We test the effect of a large 
number of genetic variants affecting the iron-related measures of serum iron concentration, 
transferrin (the major iron transporter), ferritin (which reflects iron storage in bone marrow) 
and transferrin saturation (ratio between serum iron and total iron binding capacity) on AD 
risk, in combination using a genetic profile score (GPS) approach. Variants are selected from 
an iron GWAS meta analysis discovery cohort [30] (n=23,986) and tested in large 
independent target AD case-control datasets (n=9,251). In addition we test for the converse 
scenario, whether those at a high genetic risk for AD have higher peripheral iron levels 
throughout life, using SNPs identified by the AD GWAS meta analysis discovery cohort [26] 
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(from the International Genomics of Alzheimer’s Project, IGAP n=54,162) in an independent 
population based target sample with available iron measures (n=8893). Previously an AD 
polygenic score analysis has shown that disease prediction accuracy is greatest including 
SNPs with P value <0.5. Including the full polygenic score significantly improved prediction 
over use of APOE alone where including both APOE and PRS gave AUC=78.2% [31]. 
Examples of the AD PRS based on the IGAP discovery analysis demonstrating genetic 
overlap with other traits include neuroimaging measures of subcortical brain volumes, plasma 
C-reactive protein and lipids [32, 33].  
Finally to confirm our findings using an alternative method we used SNP Effect Concordance 
Analysis (SECA) with only the discovery datasets, to examine whether SNPs found to be 
associated with the serum iron measures are enriched within associated SNPs with AD risk, 
and vice versa. 
 
Material and Methods 
Subjects 
The AD case-control cohort comprises the datasets shown in table 1. All individuals were of 
European descent and all AD case-control cohort individuals were age ≥60 years. Controls 
were screened for dementia using either MMSE, ADAS-cog, determined to be free from 
characteristic AD plaques at neuropathological examination or had a Braak score ≤2.5. 
Individuals with AD met criteria for either probable (NINCDS-ADRDA, DSM-IV) or 
definite (CERAD) AD. Individuals classed as MCI were excluded. The WTCCC2 1958 BC 
samples are population samples aged 54 years at collection and are included as unscreened 
controls in this analysis.  
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The population based sample set comprises (a) adult twins, their spouses and first degree 
relatives who volunteered for studies on risk factors or biomarkers for physical or psychiatric 
conditions (N=8380); (b) people with self-reported endometriosis and unaffected relatives 
(N=830) [34, 35]. The mean age is 47 years (ranged 15-92 years) with 62% female. 
Biochemical markers of iron status were measured using standard clinical methods on 
Roche/Hitachi 917 or Modular P analysers [30]. Serum iron was measured by colorimetry 
with Ferrozine reagent, serum transferrin by immunoturbidimetry, and ferritin by latex 
particle immunoturbidimetry. Transferrin saturation was calculated from the iron and 
transferrin results. The values for ferritin were log transformed to produce a normal 
distribution.  
Genetic Profile Scores (GPS) 
GPS for serum iron, transferrin, transferrin saturation and ferritin (log) were calculated in 
target AD case-control cohorts, using stage 1 summary data from the discovery sample of a 
GWAS meta analysis combining 11 population based studies of biochemical markers of iron 
status, with a sample size of 23,986 [30] using the method previously described ([36] and 
supplementary methods). In brief, linkage disequilibrium based clumping was used to select 
SNPs in the discovery data, providing the most significantly associated SNP available in the 
target data set. The total score is calculated by the number of risk alleles weighted by the 
standardised per-allele effects for P value thresholds of 1x10-6, 1x10-4, 1x10-3, 0.01, 0.05, 0.1, 
0.5 and 1 (all SNPs) (Supplementary table 1).  
The AD GPS was generated in the target population based cohort using summary data from 
the AD GWAS meta analysis from the IGAP discovery sample consisting of 17,008 
Alzheimer's disease cases and 37,154 controls [26]. GPS were calculated as described above, 
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with the number of risk alleles weighted by the effect on AD risk (log odds ratio). All APOE 
associated signal was removed and APOE genotype assessed separately. 
 
APOE Genotype 
In the AD cohorts a subset of samples have available APOE genotypes (table 1) inferred from 
rs429358 and rs7412 SNPs genotyped using TaqMan SNP genotyping assays. In the 
Australian dataset APOE genotype was estimated from imputed rs429358 and rs7412 SNP 
genotypes (Supplementary methods). 
 
GPS Association analysis 
In the AD cohort data sets we tested for an association between iron, transferrin, transferrin 
saturation and ferritin GPS at each P value threshold with AD case-control status using 
logistic regression (performed in STATA v11) controlling for age, sex, and four ancestry 
principal components. Results for each dataset were combined in a Meta analysis allowing a 
test for between study heterogeneity (STATA METAN specifying a random effects model). 
Finally all datasets were combined in a mega analysis also controlling for study. In addition 
we separately assessed the effect of the three iron level influencing variants that have 
previously been shown to associate with PD risk [22]. We tested for an association with the 
following SNPs; HFE rs1800562, HFE rs1799945, and TMPRSS6 rs855791 using logistic 
regression under an additive model and then combined the three variants in a GPS. To 
investigate any potential interaction effect of APOE ε4 genotype we also repeated these 
analyses controlling for APOE ε4 carrier status and also in APOE ε4 positive and APOE ε4 
negative groups. 
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In the population based dataset we tested for an association of AD GPS and number of APOE 
ε4 alleles with peripheral iron measures (iron, transferrin, transferrin saturation and ferritin) 
using Genome-wide Efficient Mixed Model Association algorithm (GEMMA) software [37]. 
The sample contains related individuals including monozygotic and dizygotic twin pairs, and 
other first degree relatives. We used linear mixed model regression using the likelihood ratio 
test, including sex, age and four ancestry principal components as covariates and controlling 
for family structure using a genetic relatedness matrix estimated from genome wide 
genotypes.  
 
SNP effect concordance analysis (SECA) 
We carried out SECA analysis of large scale GWAS meta analysis summary statistics to 
examine the genetic overlap between AD and each iron measure using the default approach 
[38]. SECA allows a larger sample size to be examined without the need for individual level 
genotype data. The GWAS meta-analysis results for AD (meta analysis N=74,046) [26] and 
iron measures (iron, transferrin, transferrin saturation and ferritin, meta analysis N=23,986) 
[30] were used to test for an excess of SNPs associated in the AD and iron phenotype data 
sets, and whether the SNP effect directions are concordant. SNP effects across the two 
GWAS summary results were aligned (AD and iron) to the same effect allele and 
independent SNPs were extracted via LD clumping identifying a subset of independent SNPs 
with the most significant P-values in the AD dataset. Restricting to SNPs associated with 
P1≤0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 in the AD dataset, exact binomial 
statistical tests determine whether there is an excess of SNPs associated in both datasets for 
the subset of SNPs associated with P2≤0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0 
in the iron dataset. Fisher’s exact test is then used to determine whether there is an excess of 
SNPs where the effect directions are concordant across the datasets for each P value subset.  
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Due to the larger sample size the AD GWAS summary statistics were initially used as dataset 
1, and each of the iron measures as dataset 2, providing the greatest possible power. Because 
the analysis is restricted to those SNPs which are most highly associated in dataset 1, we also 
repeated the analysis with the iron GWAS summary statistics as dataset 1 (in case of a 
scenario where SNPs strongly affecting iron phenotypes had an effect on AD risk, but SNPs 
strongly affecting AD risk did not affect iron phenotypes).   
 
Results 
Genetic profile score (GPS) analysis 
The discovery GWAS meta analysis datasets used in the study contain large sample sizes (in 
total 54,162 for AD and 23,986 for serum iron status) and show both AD and serum iron 
measures to have a strong polygenic components27, 31. For serum iron measures using 
replication cohorts, the lead SNPs at the 11 significant loci explained 3.4, 7.2, 6.7 and 0.9% 
of the phenotypic variance for iron, transferrin, saturation and (log-transformed) ferritin, 
respectively[30]. There is large deviation from the expected distribution of association test 
statistics compared to observed values, with association signals observed far below the level 
of genome-wide significance (figure 1). Therefore using SNPs below genome-wide 
significance will increase power to detect an association.  
Association analysis conducted in each AD disease case-control data set identified no effect 
of any serum iron status GPS (serum iron, transferrin, ferritin and transferrin saturation) on 
AD risk, and the Meta analysis identified no significant between study heterogeneity 
(Supplementary figure 1). When combined in a mega analysis no effect of any serum iron 
status GPS (serum iron, transferrin, ferritin and transferrin saturation) on AD risk was 
identified with a sample size of 6,381 controls and 2,870 AD cases (Table 3). Controlling for 
APOE genotype did not significantly affect the results, and no significant association was 
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identified in separate APOE ε4 carrier and non-carrier groups (data not shown). Previously 
three iron level influencing genetic variants (HFE rs1800562, HFE rs1799945, and 
TMPRSS6 rs855791) have been shown to be associated with PD risk[22]. There was no 
association of these SNPs with AD status in our dataset and no interaction identified with 
APOE ε4 status (Supplementary Table 2). In addition, the GPS constructed from these three 
SNPs did not have an effect on AD risk (Supplementary Table 2).  
There was no association of AD GPS or APOE ε4 with any peripheral iron measure (Table 
4).  
 
SNP Effect Concordance Analysis (SECA) 
In agreement with the GPS analysis we did not identify any significant pleiotropy between 
datasets or concordant effects using SECA. We tested for an excess of SNPs associated with 
AD also associating with iron phenotypes. Using a binomial test we compared the AD dataset 
with each of the iron phenotype datasets in turn examining 144 SNP subsets (testing twelve P 
value threshold combinations). No SNP sets were found to have nominally significant 
pleiotropy (figure 2). Using Fisher’s test we also tested for an excess of SNPs where the 
effect directions (BETA) are concordant between SNP subsets in each dataset. Again we 
identified no significant concordance (supplementary figure 2). Additionally no significant 
pleiotropy or concordant effects were seen when switching the primary dataset, i.e. testing for 
an excess of SNPs associated with each iron phenotype also associating with AD. 
 
  
Discussion 
It is becoming increasingly clear from investigations of iron homeostasis and recent advances 
in iron imaging methods that iron dysregulation is an important feature of AD, and therefore 
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lowering of iron content in the brain is a potential therapeutic target [39]. But there is limited 
understanding of the importance of peripheral iron levels in AD risk, and whether prolonged 
increased or decreased iron levels may be a risk factor for AD. We investigated whether there 
is a shared genetic basis between AD and peripheral iron levels using a PRS approach. We 
identified no effect of genetic variants affecting peripheral iron biomarkers (including iron, 
transferrin, transferrin saturation and ferritin) on AD risk. Nor did we find increased serum 
iron levels in those who are at increased genetic risk of developing AD, including both APOE 
ε4 carriers and those with a higher load of other common risk variants. In addition, in an 
investigation of the genetic overlap between AD and each iron measure, we do not find any 
significant overlap of genetic loci from the results of large-scale GWAS meta analysis 
studies.  
Taken together, our results suggest that the causes of variation in brain iron that might 
contribute to AD are distinct from those causing variation in circulating iron (serum iron) or 
in iron stores in bone marrow or other organs (serum ferritin). Iron retention is complex in 
different organs, and our current data on peripheral iron measurement cannot exclude 
causation by other genes that affect iron levels in the brain that are not reflected by serum 
values. In addition the peripheral iron measurements used are standard clinical pathology 
measures. Non-standard and possibly more direct measures (such as transferrin saturation 
using size exclusion chromatography-inductively coupled plasma-mass spectrometry) have 
been shown to be more sensitive to differences in the blood between AD patients and controls 
[15].  
It is also possible that, even if iron is not a primary cause of increase in AD risk, it 
accumulates after the initiation of cell damage by other mechanisms, and exacerbates it. 
Evidence for this comes from recent work showing that once Aβ forms aggregates they 
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induce iron accumulation [40]. Iron-related therapies could still be relevant for patients who 
are in the early stages of AD. 
 
Iron accumulation in tissues is a feature of many diseases, and may prove to be causal for 
some. Our current results for AD are in contrast to previous evidence of a causal association 
of increased peripheral iron measures with a decreased risk of Parkinson’s disease (PD) [22]. 
The authors hypothesised that low peripheral iron may decrease neuronal iron storage though 
a reduction in ferritin, resulting in free iron accumulation in the brain. To investigate whether 
a similar effect exists for AD we tested a larger number of iron-affecting variants against the 
most recent GWAS meta analysis on AD risk. These explain a larger proportion of the 
variance and therefore we would expect them to have more power to detect any effect.  
 
However, our analysis has limitations that need to be considered. Firstly, the multi-SNP GPS 
includes a large number of genetic variants of unknown effect or multiple effects, therefore 
we cannot rule out that as well as affecting iron levels, some also affect AD risk though other 
pathways and could potentially do so in opposite directions. To attempt to address this issue 
we also tested for an effect of three genetic variants (in HFE and TMPRSS6) known to have a 
direct role in peripheral iron levels and previously shown to have an effect on PD risk [22], 
where we also did not find an effect. In addition we cannot rule out the possibility that other 
genomic variations such as epigenetic dysregulation affect iron levels which are then causal 
for AD.  
 
Secondly, as in other complex diseases and phenotypes, discovered genetic variants only 
represent a small proportion of the variance in both iron levels and AD risk. This study 
utilizes summary data from the two largest GWAS meta analysis discovery cohorts for both 
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AD and biochemical markers of iron status (total sample sizes of 54,162 and 23,986 
respectively [26, 30]) to compute comprehensive GPS. In addition the GPS were applied to 
large samples with individual level genotype and phenotype data (For AD cases-control: 
2813 AD cases, and 6438 controls (of which 4926 are unscreened for AD, aged 54), and 
≥8751 for iron measures). Even so, we cannot rule out a small effect that is not detectable 
with this sample size.  
 
Thirdly, effects on iron in relevant brain areas may differ from effects on circulating iron or 
iron in other organs. Previous studies identified an association between iron accumulation in 
the basal ganglia of elderly men and peripheral iron measures [13]. However, only 9% of the 
variance of cerebrospinal fluid ferritin can be explained by plasma ferritin [9], highlighting 
the separation between these compartments. It is also possible that there are genetic loci more 
relevant to iron-homeostasis in elderly people, as the sample used to construct the iron 
phenotypes GPS have a mean age of 47.  
Our results suggest that there is not a causal connection between lifetime peripheral iron 
measures and increased risk of AD. We did not replicate the previous finding of an effect of 
HFE SNPs on risk of AD and an epistatic interaction for risk with APOE ε4 genotype, but we 
cannot yet rule out an association of HFE SNPs with AD age of onset or phenotypic 
interactions [25, 27, 28].  
It has been suggested that public recommendations for AD risk reduction should caution the 
use of iron supplementation for those whom it is not required [18, 41, 42].  Dietary patterns 
such as a Mediterranean diet and reduced red meat consumption that associate with lower AD 
risk do tend to have a low iron intake, but also have other unrelated health benefits for 
example high intake of vegetables and low saturated fat. Consistent with our genetic findings, 
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there is no clear evidence that dietary intervention affecting iron intake alters the risk of AD 
[18]. More work is needed to assess the effect of iron on the progression (as opposed to the 
initiation) and age of onset of AD. 
 
In conclusion, although iron deposition is an important feature of AD brain tissues, these 
results suggest that there is not a significant causal relationship between lifetime peripheral 
iron levels and AD.   
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Cohorts N AD 
case
s 
N 
Control
s 
Mean Age 
(range, SD) 
% 
Female 
APOE ε4 
Frequency 
Genetic and Environmental 
Risk for Alzheimer’s disease 
(GERAD1) [43] 
2361 942 79.0 (60-108, 
7.7) 
64.6 AD=0.33 (N=2183) 
CN=0.13 (N=906) 
Innovative Medicines in 
Europe (AddNeuroMed) [44] 
223 280 77.5 (60-98, 
6.9) 
59.8 AD=0.33 (N=217) 
CN=0.15 (N=143) 
Kings Health Partners- 
Dementia Case Register 
(KPH-DCR) [45]  
64 85 79.5 (61-93, 
6.8) 
59.7 AD=0.38 (N=52) 
CN=0.14  (N=65) 
Alzheimer’s Disease 
Neuroimaging Initiative 
(ADNI) [46] 
165 205 76.3 (60-91, 
6.0) 
44.9 AD=0.42 (N=165) 
CN=0.14 (N=204) 
Wellcome Trust Case 
Control Consortium 1958 
British Birth Cohort 
(WTCCC2) [47] 
0 4926 54 (all 54) 49.7 CN=0.16 (N=4862) 
 
Table 1. Alzheimer’s disease case-control cohort data sets. 
The Alzheimer’s disease cohorts which contributed data to the assessment of the effect of iron 
genetic profile scores to risk of AD. The APOE ε4 frequency is shown for the individuals where APOE 
genotype data was available, with the sample size in brackets. 
Abbreviations: AD, Alzheimer’s disease; CN, controls. 
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Serum measure N Mean Range  SD 
Iron (μmol/L) 8751 19.54 0.10-50.50 6.74 
Transferrin Saturation (%)  8800 28.71 0.12-95.3 10.80 
Transferrin (g/L) 8891 2.82 1.40-5.19 0.44 
Ferritin (log10) (μg/L) 8892 2.00 0.00-3.26 0.50 
 
Table 2. Serum iron measures in the Australian data set 
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GPS 
Association with AD risk (n=9251) 
β SE P 
Iron p≤1 0.04 0.03 0.278 
p≤0.5 0.03 0.03 0.365 
p≤0.1 0.01 0.03 0.868 
p≤0.05 0.02 0.03 0.638 
p≤0.01 -0.01 0.03 0.695 
p≤0.001 -0.01 0.03 0.839 
p≤0.0001 0.02 0.03 0.624 
p≤0.000001 0.02 0.33 0.632 
Transferrin Saturation p≤1 0.03 0.03 0.291 
p≤0.5 0.03 0.03 0.330 
p≤0.1 0.03 0.03 0.381 
p≤0.05 0.02 0.03 0.584 
p≤0.01 0.02 0.03 0.510 
p≤0.001 0.02 0.03 0.590 
p≤0.0001 0.02 0.03 0.628 
p≤0.000001 0.03 0.03 0.408 
Transferrin p≤1 0.00 0.03 0.933 
p≤0.5 0.00 0.03 0.950 
p≤0.1 0.02 0.03 0.589 
p≤0.05 0.01 0.03 0.797 
p≤0.01 -0.02 0.03 0.517 
p≤0.001 -0.03 0.03 0.299 
p≤0.0001 -0.03 0.03 0.404 
p≤0.000001 -0.02 0.03 0.467 
Ferritin p≤1 0.02 0.03 0.577 
p≤0.5 0.03 0.04 0.465 
p≤0.1 0.03 0.04 0.465 
p≤0.05 0.05 0.04 0.196 
p≤0.01 0.03 0.03 0.347 
p≤0.001 0.03 0.03 0.355 
p≤0.0001 0.03 0.03 0.377 
p≤0.000001 0.04 0.03 0.170 
 
Table 3. The association of serum iron measure genetic profile score (GPS) at different P value 
thresholds with AD risk.  
The association analysis was carried out using logistic regression controlling for sex, age,four 
ancestry principal components and study 
Abbreviations: β, standardised Beta  
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Serum Iron Measure AD GPS N β SE P 
Iron p≤1 8751 0.02 0.01 0.153 
p≤0.5 8751 0.02 0.01 0.148 
p≤0.1 8751 0.01 0.01 0.349 
p≤0.05 8751 0.01 0.01 0.594 
p≤0.01 8751 0.00 0.01 0.747 
p≤0.001 8751 0.01 0.01 0.405 
p≤0.0001 8751 0.01 0.01 0.615 
p≤0.000001 8751 0.02 0.01 0.119 
APOE ε4 8494 0.00 0.01 0.843 
Transferrin Saturation p≤1 8800 371.45 224.20 0.097 
p≤0.5 8800 201.12 136.43 0.140 
p≤0.1 8800 46.40 54.11 0.391 
p≤0.05 8800 13.37 38.99 0.732 
p≤0.01 8800 2.82 18.46 0.878 
p≤0.001 8800 0.76 6.58 0.908 
p≤0.0001 8800 0.25 2.15 0.908 
p≤0.000001 8800 3.19 1.27 0.012 
APOE ε4 8531 0.02 0.02 0.477 
Transferrin p≤1 8891 -218.75 225.19 0.331 
p≤0.5 8891 -78.29 137.03 0.568 
p≤0.1 8891 9.86 54.36 0.856 
p≤0.05 8891 23.12 39.16 0.555 
p≤0.01 8891 5.87 18.52 0.751 
p≤0.001 8891 16.29 6.58 0.013 
p≤0.0001 8891 4.97 2.15 0.021 
p≤0.000001 8891 -1.77 1.28 0.166 
APOE ε4 8619 -0.02 0.02 0.466 
Ferritin p≤1 8892 156.22 192.51 0.417 
p≤0.5 8892 81.98 117.14 0.484 
p≤0.1 8892 35.61 46.42 0.442 
p≤0.05 8892 7.49 33.47 0.822 
p≤0.01 8892 11.05 15.85 0.485 
p≤0.001 8892 2.53 5.64 0.654 
p≤0.0001 8892 -0.64 1.84 0.728 
p≤0.000001 8892 0.85 1.09 0.435 
APOE ε4 8621 0.01 0.02 0.486 
 
Table 4. The association of AD GPS at different P value thresholds (excluding APOE) and 
number of APOE ε4 alleles with iron phenotypes. The association analysis was carried out using 
linear mixed models implemented in GEMMA (genome-wide efficient mixed-model association) [37] 
using the likelihood ratio test. Family relationships were controlled for using a genetic relatedness 
matrix estimated from genotypes. Sex, age and four ancestry principal components were also 
included as covariates. 
Abbreviations: β, standardised Beta 
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Figure 1. Q-Q plots of the association P-values from the discovery GWAS meta analyses. 
Including the GWAS meta analysis of biochemical markers of iron status[30] and the International 
Genomics of Alzheimer’s Project (IGAP)[26]. SNPs in the APOE region (within 500kb either side of 
APOE locus) are excluded from the AD plot. The red line is the line of equivalence, 
observed=expected.  
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Figure 2. Genetic overlap between dataset 1 (AD) and dataset 2 (Serum iron) 
In the SECA analysis exact binomial statistical tests are performed to determine whether there is an 
excess of SNPs associated in both datasets for 144 SNP subsets from 12x12 P-value threshold 
combinations. A binomial test ‘heatmap’ plot is generated to graphically summarize the proportion of 
SNP subsets with an excess  [observed(obs)≥expected (exp)] or deficit (obs<exp) number of 
associated SNPs, and empirical P-values (adjusted for testing all 144 subsets) are calculated via 
permutation. 
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Supplementary Methods 
1. GWAS data and imputation methods.  
All AD cohorts were genotyped on the Illumina 610-Quad or Illumina 666W-Quad chip. All 
GWAS data were imputed to the 1000G phase 1 integrated reference panel (April 2012 
National Center for Biotechnology Information  [NCBI] build 37). As genotype data was 
used from multiple sources stringent quality control filters were applied. GWAS data quality 
control, merging and imputation steps have been described in detail previously [1]. 
The population based sample set was genotyped on several different genome wide platforms 
(Illumina Human317K, HumanCNV370v1, HumanCNV370-Quadv3, Human610-Quadv1). 
Sample QC included omitting ethnic outliers, duplicate samples, and samples with 
unresolved sex, identity or pedigree issues (if not correctable after investigation). Mendelian 
error genotypes per marker were removed across families. Exclusion criteria for markers 
were MAF<1%, call rate <0.99, P HWE<10-6, mean GenCall score <0.7. Approximately 
281,000 markers are observed in all genotyping projects. Imputation of approximately 
12,000,000 SNPs was carried out using the 1000 Genomes reference panel (August 4, 2010 
release with European haplotypes) using minimac. After imputation 7,262,077 markers 
passed QC (R2≥0.3). 
In the Australian dataset APOE genotype was estimated from imputed rs429358 and rs7412 
SNP genotypes, which are not perfectly imputed (R2 values are 0.68 and 0.63 respectively). 
We found the concordance between the imputed and genotyped APOE ε4 was 93%.  This 
was calculated by comparing genotyped and imputed APOE (from the Queensland Twin 
Imaging (QTIM) cohort, which had available directly genotyped APOE and was included in 
the same imputation dataset) in a sample size of 3879 [2]. 
2. Genetic Profile Scores 
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SNPs with MAF≤0.02, genotyping rate≤0.99 and HWP<1x10-6 in the target sample were 
excluded. Linkage Disequilibrium (LD) based clumping was carried out on all SNPs in the 
discovery data, providing the most significantly associated SNP available in the target data 
set, in each region of LD (using PLINK clumping command with a pairwise r2 threshold of 
0.2 and a physical distance threshold of 300kb). SNPs were checked for flip strands between 
the discovery and target sample. The total score is calculated by the number of risk alleles 
weighted by the standardised per-allele effects, beta using PLINK score function. The risk 
score was calculated for P value thresholds of 1x10-6, 1x10-4, 1x10-3, 0.01, 0.05, 0.1, 0.5 and 
1 (all SNPs). The iron GPS were calculated separately in three imputed AD case-control 
datasets (as described in detailed imputation methods [1]; set 1 consists of GERAD1 and 
WTCCC2, set 2 of ADNI and part of AddNeuroMed, and set 3 the remaining Addneuromed 
and KPH-DCR). SNPs within 500kb either side of the APOE locus were excluded from the GPS to 
ensure all APOE associated signal was removed. The APOE effect is not well represented within a 
GRS owing to the ε4 allele being a diplotype acting under a co-dominant genetic model, and with a 
much larger effect size than the other common AD risk variants[3]. 
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Supplementary Tables and Figures 
AD  
P Value Threshold Australian  
p≤1 833350 
p≤0.5 483466 
p≤0.1 127186 
p≤0.05 69634 
p≤0.01 17566 
p≤0.001 2108 
p≤0.0001 514 
p≤0.000001 42 
Fe 
P Value Threshold GERAD1--WTCCC AddNeuroMed_1 AddNeuroMed2-DCR ADNI 
p≤1 252456 244606 253672 240836 
p≤0.5 179022 172554 178822 170344 
p≤0.1 53802 51316 53124 50772 
p≤0.05 30488 28972 29954 28656 
p≤0.01 7990 7576 7854 7504 
p≤0.001 1222 1172 1218 1158 
p≤0.0001 276 264 284 256 
p≤0.000001 92 88 98 82 
Sat 
P Value Threshold GERAD1- WTCCC AddNeuroMed_1 AddNeuroMed2-DCR ADNI 
p≤1 253590 240732 240918 236990 
p≤0.5 179912 170458 170380 168114 
p≤0.1 54280 51132 51100 50692 
p≤0.05 30986 28980 28996 28742 
p≤0.01 8190 7670 7664 7594 
p≤0.001 1302 1214 1202 1214 
p≤0.0001 352 338 324 330 
p≤0.000001 164 158 148 148 
Trans 
P Value Threshold GERAD1- WTCCC AddNeuroMed_1 AddNeuroMed2-DCR ADNI 
p≤1 254286 242506 242854 238678 
p≤0.5 182046 173622 174096 171426 
p≤0.1 57478 54324 54370 53534 
p≤0.05 33606 31760 31766 31414 
p≤0.01 9236 8732 8754 8654 
p≤0.001 1620 1534 1536 1530 
p≤0.0001 420 400 398 388 
p≤0.000001 162 148 158 150 
Ferri 
P Value Threshold GERAD1- WTCCC AddNeuroMed_1 AddNeuroMed2-DCR ADNI 
p≤1 242692 232648 232986 228938 
p≤0.5 173016 165518 165664 163236 
p≤0.1 53188 50292 50072 49560 
p≤0.05 30394 28840 28736 28380 
p≤0.01 8140 7702 7690 7622 
p≤0.001 1204 1138 1138 1126 
p≤0.0001 212 198 202 198 
p≤0.000001 38 40 36 38 
Supplementary Table 1. Number of SNPs included in each Genetic profile score for each 
imputation dataset. 
Abbreviations: AD, Alzheimer’s disease; Fe, Iron; sat, Transferrin Saturation; Trans, Transferrin; Ferri, 
Ferritin. 
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Variant 
All (n=9251) APOE ε4 +ve 
(n=3676) 
APOE ε4 –ve 
(n=5575) 
β SE P β SE P β SE P 
HFE rs1799945 
 
-0.009 0.062 0.885 -
 
0.095 0.320 0.023 0.090 0.803 
HFE 
 
0.098 0.090 0.279 0.105 0.138 0.444 0.081 0.133 0.540 
TMPRSS6 rs855791 -0.048 0.046 0.295 -
 
0.069 0.962 -
 
0.067 0.164 
Three SNP GPS  -0.002 0.032 0.960 -
 
0.049 0.900 -
 
0.048 0.691 
 
Supplementary Table 2. The association of iron influencing mutations with AD risk. 
Analysis was carried out using logistic regression controlling for sex, age,four ancestry principal 
components and study. Genotypes were tested under an additive model with the risk allele being that 
associated with increased iron levels. The genetic profile score (GRS) is generated from the three 
genotypes. Standardised Betas (β) are shown. 
 
 
 
Supplementary figure 1. Meta analysis for the effect of Serum iron measures genetic profile 
scores at P≤0.5 threshold. 
The meta-analysis used effect size estimates and standard errors with a random effects model. ES 
represents the effect size which is the combined β value. I2 is a measure of between study 
heterogeneity. Results shown for P≤0.5 threshold only, but no significant association or heterogeneity 
between datasets was observed at any P value threshold. Group 1 is GERAD1 together with 
WTCCC21958 British Birth Cohort, Group 2 is AddNeuroMed (second batch) with DCR, Group 3 is 
AddNeuroMed (first batch) and Group 4 is ADNI.  
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Supplementary Figure 2. SNP effect direction between dataset 1 (AD) and dataset 2 (Serum 
iron) 
In the SECA analysis Fisher’s exact statistical tests are performed to determine whether there is an 
excess of SNPs where the effect directions (BETA) are concordant across dataset1 and dataset2  for 
144 SNP subsets from 12x12 P-value threshold combinations. A Fisher’s test ‘heatmap’ plot is 
generated to graphically summarize the proportion of SNP subsets with concordant (Fisher’s test 
odds ratio, ORFT≥1) and discordant (ORFT<1) SNP effects, and an empirical P-value (PFTsig-permuted) 
is calculated via permutation for the observed number of subsets (nFTsig) with nominally significant 
concordance (ORFT≥1and PFT≤0.05).  
 
 
 
